

SUPPLEMENTAL INFORMATION ONLINE-ONLY CONTENT

Effects of white matter hyperintensities on 90-day functional outcome after large vessel and non-large vessel stroke

Christoph J. Griessenauer^{1,2}, David McPherson³, Andrea Berger⁴, Ping Cuiper⁴, Nelson Sofoluke¹, Matthew D. Adams³, Saran Kunaprayoon³, Ramin Zand⁵, Jiang Li⁶, Vida Abedi^{6,7}, Oded Goren¹, Clemens M. Schirmer¹, Kathleen Donahue⁸, Marco Nardin⁸, Anne-Karin Giese⁸, Markus D. Schirmer⁸, Natalia S. Rost⁸, Philipp Hendrix^{1,9}

¹Department of Neurosurgery, Geisinger, Danville, PA

²Research Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria

³Geisinger Commonwealth School of Medicine, Scranton, PA

⁴Biostatistics Core, Geisinger, Danville, PA

⁵Department of Neurology, Geisinger, Danville, PA

⁶Department of Molecular and Functional Genomics, Geisinger, Danville, PA

⁷Biocomplexity Institute, Virginia Tech, Blacksburg, VA, USA.

⁸Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

⁹Department of Neurosurgery, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg/Saar, Germany

Supplemental Tables

Table 1. Variables used in Multiple Imputation Process

Variable Name	Missing % (Out of n = 1601)
ReStroked_within_1year	0.0%
TOAST_Stroke_Subtype	0.0%
Year_admitted(year)	0.0%
Age	0.0%
Female	0.0%
BMI_30above	0.0%
Intracranial_Arterio	0.0%
MoyaMoya	0.0%
Dementia	0.0%
Parkinsons	0.0%
Peripheral_Vasc_Disease	0.0%
Anema	0.0%
Procoagulant	0.0%
COPD	0.0%
Sleep_Apnea	0.0%
Hypertension	0.0%
Diabetes_mellitus2	0.0%
Carotid_Stenosis	0.0%
Dyslipidemia	0.0%
Coronary_artery_disease	0.0%
Atrial_Fib	0.0%
prior_TIA	0.0%
prior_IS_HS_CVA	0.0%
Family_History	0.0%
Smoking_Status	1.8%
Drinking	5.6%
NIHS_Admission(nihss_at_admission)	4.6%
LVO	0.0%
LVO_prox_Circ_IM1M2(anterior_lvo)	0.0%
Stroke_Therapy_ivTPA_Embolectomy	0.0%
secondary_ICH	0.0%
discharge_ASPIRIN	0.0%
discharge_CLOPIDOGREL	0.0%
discharge_Anticoagulation	0.0%
discharge_Brillinta	0.0%
discharge_Prasugrel	0.0%
Outcome_90d_mRS02	0.0%
Outcome_90d_mRS6	0.0%
HOME_Platelets_None_Mono_Duo	0.0%
HOME_Anticoag	0.0%
HOME_Statins	0.0%
HOME_AT1_ACEinhib	0.0%
HOME_Beta_Blocker	0.0%

HOMe_Metformin	0.0%
Home_Oral_Antidiabetics	0.0%
WMH_volume	19.7%
Stroke_sequence	0.0%

Table 2: Comparison of the characteristics of strokes with and without WMH volumes

	WMH Volume Missing (n = 316)	WMH Volume Present (n = 1285)	P-value*
Age, Mean (SD)/Median (IQR)	70.1 (14.0)/ 72 (60, 81)	67.1 (13.2)/ 68 (58, 77)	0.0003
Male, n (%)	169 (53.5)	644 (50.1)	0.2865
History of Hypertension, n (%)	254 (80.4)	1010 (78.6)	0.5379
History of Type II Diabetes, n (%)	129 (40.8)	492 (38.3)	0.4394
Dyslipidemia, n (%)	221 (69.9)	927 (72.1)	0.4437
Current or Former Smoker, n (%)	202 (66.2)	752 (59.4)	0.0311
<i>Missing, n</i>	<i>11</i>	<i>18</i>	
Alcohol Consumption, n (%)	103 (35.0)	449 (36.9)	0.5895
<i>Missing, n</i>	<i>22</i>	<i>67</i>	
BMI \geq 30, n (%)	163 (51.6)	592 (46.1)	0.0894
Peripheral Vascular Disease, n (%)	34 (10.8)	127 (9.9)	0.6762
Coronary Artery Disease, n (%)	125 (39.6)	352 (27.4)	< 0.0001
Atrial Fibrillation, n (%)	113 (35.8)	242 (18.8)	< 0.0001
Carotid Stenosis, n (%)	121 (38.3)	486 (37.8)	0.8971
Intracranial Atherosclerotic Stenosis, n (%)	89 (28.2)	394 (30.7)	0.4120
Anemia, n (%)	55 (17.4)	188 (14.6)	0.2211
Pro-Coagulant Coagulation Disorder, n (%)	15 (4.7)	56 (4.4)	0.7607
COPD, n (%)	53 (16.8)	135 (10.5)	0.0033
Sleep Apnea, n (%)	38 (12.0)	132 (10.3)	0.3601
Family History of Stroke, n (%)	68 (21.5)	290 (22.6)	0.7072
Prior TIA, n (%)	47 (14.9)	144 (11.2)	0.0809
Prior Stroke (hemorrhagic or ischemic), n (%)	75 (23.7)	267 (20.8)	0.2513
mRS 0-2 (Favorable)	167 (52.8)	907 (70.6)	< 0.0001

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 3. Baseline demographic and stroke risk factor characteristics among encounters with values of WMH (n=1,285)

	Entire Cohort (n = 1285)	mRS 0-2 Favorable (n = 907)	mRS 3-6 Unfavorable (n = 378)	P-value*
Age (years) (median [IQR], mean \pm SD)	68 [58 – 77], 67.1 \pm 13.2	66 [57 – 75], 65.4 \pm 13.2	73 [63 – 81], 71.4 \pm 12.4	< 0.0001
Females, n (%)	641 (49.9%)	430 (47.4%)	211 (55.8%)	0.0070
History of hypertension, n (%)	1010 (78.6%)	684 (75.4%)	326 (86.2%)	< 0.0001
Diabetes mellitus type 2, n (%)	492 (38.3%)	311 (34.3%)	181 (47.9%)	< 0.0001
Dyslipidemia, n (%)	927 (72.1%)	640 (70.6%)	287 (75.9%)	0.0558
Current or former smoker, n (%)	752 (58.5%)	540 (60.1%)	212 (57.6%)	0.4497
<i>Missing, n</i>	18	8	10	
Alcohol consumption, n (%)	449 (36.9%)	341 (39.5%)	108 (30.4%)	0.0032
<i>Missing, n</i>	67	44	23	
BMI \geq 30, n (%)	592 (46.1%)	419 (46.2%)	173 (45.8%)	0.9024
Peripheral vascular disease, n (%)	127 (9.9%)	74 (8.2%)	53 (14.0%)	0.0020
Coronary artery disease, n (%)	352 (27.4%)	223 (24.6%)	129 (34.1%)	0.0006
Atrial fibrillation, n (%)	242 (18.8%)	147 (16.2%)	95 (25.1%)	0.0003
Carotid stenosis, n (%)	486 (37.8%)	344 (37.9%)	142 (37.6%)	0.9497
Intracranial atherosclerotic stenosis, n (%)	394 (30.7%)	273 (30.1%)	121 (32.0%)	0.5072
Anemia, n (%)	188 (14.6%)	100 (11.0%)	88 (23.3%)	< 0.0001
Pro-coagulant coagulation disorder, n (%)	56 (4.4%)	34 (3.8%)	22 (5.8%)	0.1009
COPD, n (%)	135 (10.5%)	80 (8.8%)	55 (14.6%)	0.0036
Sleep apnea, n (%)	132 (10.3%)	84 (9.3%)	48 (12.7%)	0.0697
Family history of stroke, n (%)	290 (22.6%)	193 (21.3%)	97 (25.7%)	0.0923
Prior TIA, n (%)	144 (11.2%)	95 (10.5%)	49 (13.0%)	0.2075
Prior stroke (hemorrhagic or ischemic), n (%)	267 (20.8%)	164 (18.1%)	103 (27.3%)	0.0003

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 4. Imaging, stroke, and treatment characteristics among encounters with values of WMH (n=1,285)

	Entire Cohort (n = 1285)	mRS 0-2 Favorable (n = 907)	mRS 3-6 Unfavorable (n = 378)	P-value*
White matter hyperintensity volume (median [IQR])	3.13 [1.02 – 7.50]	2.50 [0.77 – 6.44]	4.44 [1.93 – 9.53]	< 0.0001
LVO, n (%)	280 (21.8%)	168 (18.5%)	112 (29.6%)	< 0.0001
Anterior (IM1M2) LVO, n (%)	183 (14.2%)	108 (11.9%)	75 (19.8%)	0.0003
TOAST Subtype, n (%)				
Cardioembolism	366 (28.5%)	252 (27.8%)	114 (30.2%)	0.4197
Large-artery atherosclerosis	318 (24.8%)	224 (24.7%)	94 (24.9%)	
Small vessel occlusion	234 (18.2%)	176 (19.4%)	58 (15.3%)	
Stroke of undetermined etiology	319 (24.8%)	224 (24.7%)	95 (25.1%)	
Stroke of other determined etiology	48 (3.7%)	31 (3.4%)	17 (4.5%)	
NIHSS at admission (median [IQR], mean ± SD)	2 [1 – 5], 4.1 ± 5.2	2 [1 – 4], 3.2 ± 4.2	4 [2 – 9], 6.3 ± 6.6	< 0.0001
<i>Missing, n</i>	49	29	20	
NIHSS at admission, n (%)				
No stroke symptoms (0)	259 (21.0%)	209 (23.8%)	50 (14.0%)	< 0.0001
Minor stroke (1-4)	612 (49.5%)	470 (53.5%)	142 (40.0%)	
Moderate stroke (5-15)	299 (24.2%)	173 (19.7%)	126 (35.2%)	
Moderate/severe stroke (16-20)	38 (3.1%)	17 (1.9%)	21 (5.9%)	
Severe stroke (21-42)	28 (2.3%)	9 (1.0%)	19 (5.3%)	
<i>Missing</i>	49 (3.8%)	29 (3.2%)	20 (5.3%)	
Treatment, n (%)				
IV tPA	116 (9.0%)	84 (9.3%)	32 (8.5%)	0.5968
Mechanical thrombectomy	11 (0.9%)	9 (1.0%)	2 (0.5%)	
IV tPA and mechanical thrombectomy	17 (1.3%)	10 (1.1%)	7 (1.9%)	
None	1141 (88.8%)	804 (88.6%)	337 (89.2%)	
IV tPA Treatment, n (%)	133 (10.4%)	94 (10.4%)	39 (10.3%)	1.0000
TICI reperfusion score among thrombectomy treatments, n (%)				
mTICI 0	2 (7.1%)	0 (0.00%)	2 (22.2%)	0.0042
mTICI 1	0 (0.00%)	0 (0.00%)	0 (0.00%)	
mTICI 2A	2 (7.1%)	0 (0.00%)	2 (22.2%)	
mTICI 2B	11 (39.3%)	7 (36.8%)	4 (44.4%)	
mTICI 3	13 (46.4%)	12 (63.2%)	1 (11.1%)	
Secondary intracerebral hemorrhage, n (%)	112 (8.7%)	71 (7.8%)	41 (10.9%)	0.0833

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 5. Imputed data multivariable model for favorable functional outcome (all p < 0.05)

Odds Ratio Estimates (n = 1601)				
Effect	OR	95% CI		P-Value
WMH Volume (1 unit increase for volume \leq 4)	0.853	0.769	0.945	0.0005
WMH Volume (1 unit increase for volume > 4)	0.986	0.960	1.011	
Age	0.971	0.961	0.981	< 0.0001
Female	0.752	0.594	0.953	0.0181
Diabetes Mellitus Type 2	0.632	0.497	0.804	0.0002
Anemia	0.446	0.328	0.606	< 0.0001
COPD	0.650	0.460	0.918	0.0145
Sleep Apnea	0.670	0.464	0.968	0.0330
LVO	0.634	0.470	0.855	0.0029
NIHSS at Admission: Minor vs No Symptoms	0.745	0.534	1.041	< 0.0001
NIHSS at Admission: Moderate vs No Symptoms	0.302	0.208	0.437	
NIHSS at Admission: Moderate/Severe vs No Symptoms	0.117	0.059	0.235	
NIHSS at Admission: Severe vs No Symptoms	0.075	0.032	0.175	
Treatment: Mechanical Thrombectomy vs None	3.703	1.059	12.945	0.0050
Treatment: IV tPA vs None	1.942	1.255	3.006	
Treatment: IV tPA/Mechanical Thrombectomy vs None	1.820	0.660	5.015	

Table 6. Baseline demographic and stroke risk factor characteristics among all encounters without large vessel occlusion

	Entire Cohort (n = 1248)	mRS 0-2 Favorable (n = 874)	mRS 3-6 Unfavorable (n = 374)	P-value*
Age (years) (median [IQR], mean \pm SD)	69 [59 – 78], 67.9 \pm 13.5	67 [58 – 76], 66.1 \pm 13.4	74 [64 – 82], 72.1 \pm 12.9	< 0.0001
Females, n (%)	612 (49.0%)	412 (47.1%)	200 (53.5%)	0.0416
History of hypertension, n (%)	981 (78.6%)	663 (75.9%)	318 (85.0%)	0.0003
Diabetes mellitus type 2, n (%)	504 (40.4%)	317 (36.3%)	187 (50.0%)	< 0.0001
Dyslipidemia, n (%)	894 (71.6%)	626 (71.6%)	268 (71.7%)	1.0000
Current or former smoker, n (%)	738 (59.5%)	510 (58.7%)	228 (61.5%)	0.3769
<i>Missing, n</i>	8	5	3	
Alcohol consumption, n (%)	430 (36.1%)	332 (39.7%)	98 (27.5%)	<0.0001
<i>Missing, n</i>	56	38	18	
BMI \geq 30, n (%)	599 (48.0%)	414 (47.4%)	185 (49.5%)	0.5363
Peripheral vascular disease, n (%)	115 (9.2%)	70 (8.0%)	45 (12.0%)	0.0321
Coronary artery disease, n (%)	379 (30.4%)	239 (27.4%)	140 (37.4%)	0.0005
Atrial fibrillation, n (%)	273 (21.9%)	167 (19.1%)	106 (28.3%)	0.0004
Carotid stenosis, n (%)	416 (33.3%)	305 (34.9%)	111 (29.7%)	0.0770
Intracranial atherosclerotic stenosis, n (%)	327 (26.2%)	230 (26.3%)	97 (25.9%)	0.9440
Anemia, n (%)	204 (16.4%)	108 (12.4%)	96 (25.7%)	< 0.0001
Pro-coagulant coagulation disorder, n (%)	54 (4.3%)	33 (3.8%)	21 (5.6%)	0.1709
COPD, n (%)	141 (11.3%)	84 (9.6%)	57 (15.2%)	0.0061
Sleep apnea, n (%)	141 (11.3%)	86 (9.8%)	55 (14.7%)	0.0147
Family history of stroke, n (%)	279 (22.4%)	187 (21.4%)	92 (24.6%)	0.2354
Prior TIA, n (%)	153 (12.3%)	103 (11.8%)	50 (13.4%)	0.4515
Prior stroke (hemorrhagic or ischemic), n (%)	260 (20.8%)	157 (18.0%)	103 (27.5%)	0.0002

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 7. Imaging, stroke, and treatment characteristics among all encounters without large vessel occlusion

	Entire Cohort (n = 1248)	mRS 0-2 Favorable (n = 874)	mRS 3-6 Unfavorable (n = 374)	P-value*
White matter hyperintensity volume (median [IQR]) <i>Missing, n</i>	3.28 [1.13 – 7.72] 243	2.70 [0.91 – 6.68] 135	4.83 [2.29 – 10.77] 108	< 0.0001
TOAST Subtype, n (%)				0.6037
Cardioembolism	392 (31.4%)	271 (31.0%)	121 (32.4%)	
Large-artery atherosclerosis	202 (16.2%)	145 (16.6%)	57 (15.2%)	
Small vessel occlusion	259 (20.8%)	189 (21.6%)	70 (18.7%)	
Stroke of undetermined etiology	351 (28.1%)	241 (27.6%)	110 (29.4%)	
Stroke of other determined etiology	44 (3.5%)	28 (3.2%)	16 (4.3%)	
NIHSS at admission (median [IQR]) <i>Missing, n</i>	2 [1 – 5] 61	2 [1 – 4] 30	4 [1 – 7] 31	< 0.0001
NIHSS at admission, n (%)				< 0.0001
No stroke symptoms (0)	262 (22.1%)	206 (24.4%)	56 (16.3%)	
Minor stroke (1-4)	610 (51.4%)	457 (54.1%)	153 (44.6%)	
Moderate stroke (5-15)	283 (23.8%)	171 (20.3%)	112 (32.7%)	
Moderate/severe stroke (16-20)	16 (1.3%)	5 (0.6%)	11 (3.2%)	
Severe stroke (21-42)	16 (1.3%)	5 (0.6%)	11 (3.2%)	
<i>Missing</i>	61	30	31	
Treatment, n (%)				0.1440
IV tPA	121 (9.7%)	92 (10.5%)	29 (7.8%)	
Mechanical thrombectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	
IV tPA and mechanical thrombectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	
None	1127 (90.3%)	782 (89.5%)	345 (92.2%)	
IV tPA Treatment, n (%)	121 (9.7%)	92 (10.5%)	29 (7.7%)	0.1440
Secondary intracerebral hemorrhage, n (%)	76 (6.1%)	47 (5.4%)	29 (7.8%)	0.1209

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 8. Imputed data multivariable model results for favorable functional outcome for encounters without large vessel occlusion (all p < 0.05)

Odds Ratio Estimates for Not LVO Encounters (n = 1248)				
Effect	OR	95% CI		P-Value
WMH Volume (1 unit increase for volume \leq 4)	0.841	0.735	0.962	0.0005
WMH Volume (1 unit increase for volume > 4)	0.976	0.951	1.002	
Age	0.969	0.957	0.981	<.0001
Female	0.748	0.572	0.978	0.034
Diabetes Mellitus Type 2	0.598	0.456	0.784	0.0002
Carotid Stenosis	1.573	1.179	2.100	0.0021
Anemia	0.482	0.345	0.672	< 0.0001
Sleep Apnea	0.623	0.416	0.932	0.0213
NIHSS at Admission: Minor vs No Symptoms	0.895	0.624	1.282	< 0.0001
NIHSS at Admission: Moderate vs No Symptoms	0.373	0.250	0.556	
NIHSS at Admission: Moderate/Severe vs No Symptoms	0.109	0.034	0.350	
NIHSS at Admission: Severe vs No Symptoms	0.160	0.050	0.513	

Table 9. Baseline demographic and stroke risk factor characteristics among all encounters with large vessel occlusion

	Entire Cohort (n = 353)	mRS 0-2 Favorable (n = 200)	mRS 3-6 Unfavorable (n = 153)	P-value*
Age (years) (median [IQR], mean \pm SD)	67 [58 – 77], 67.2 \pm 13.2	64 [53 – 73], 63.7 \pm 12.9	73 [63 – 82], 71.8 \pm 12.2	< 0.0001
Females, n (%)	176 (49.9%)	90 (45.0%)	86 (56.2%)	0.0415
History of hypertension, n (%)	283 (80.2%)	151 (75.5%)	132 (86.3%)	0.0150
Diabetes mellitus type 2, n (%)	117 (33.1%)	58 (29.0%)	59 (38.6%)	0.0680
Dyslipidemia, n (%)	254 (72.0%)	132 (66.0%)	122 (79.7%)	0.0058
Current or former smoker, n (%) <i>Missing, n</i>	216 (65.1%) 21	138 (71.1%) 6	78 (56.5%) 15	0.0072
Alcohol consumption, n (%) <i>Missing, n</i>	122 (38.1%) 33	75 (40.8%) 16	47 (34.6%) 17	0.2951
BMI \geq 30, n (%)	156 (44.2%)	94 (47.0%)	62 (40.5%)	0.2358
Peripheral vascular disease, n (%)	46 (13.0%)	22 (11.0%)	24 (15.7%)	0.2054
Coronary artery disease, n (%)	98 (27.8%)	47 (23.5%)	51 (33.3%)	0.0426
Atrial fibrillation, n (%)	82 (23.2%)	30 (15.0%)	52 (34.0%)	< 0.0001
Carotid stenosis, n (%)	191 (54.1%)	103 (51.5%)	88 (57.5%)	0.2821
Intracranial atherosclerotic stenosis, n (%)	156 (44.2%)	88 (44.0%)	68 (44.4%)	1.0000
Anemia, n (%)	39 (11.0%)	12 (6.0%)	27 (17.7%)	0.0009
Pro-coagulant coagulation disorder, n (%)	17 (4.8%)	9 (4.5%)	8 (5.2%)	0.8050
COPD, n (%)	47 (13.3%)	20 (10.0%)	27 (17.7%)	0.0405
Sleep apnea, n (%)	29 (8.2%)	16 (8.0%)	13 (8.5%)	1.0000
Family history of stroke, n (%)	79 (22.4%)	37 (18.5%)	42 (27.5%)	0.0533
Prior TIA, n (%)	38 (10.8%)	17 (8.5%)	21 (13.7%)	0.1226
Prior stroke (hemorrhagic or ischemic), n (%)	82 (23.2%)	43 (21.5%)	39 (25.5%)	0.4456

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 10. Imaging, stroke, and treatment characteristics among all encounters with large vessel occlusion

	Entire Cohort (n = 353)	mRS 0-2 Favorable (n = 200)	mRS 3-6 Unfavorable (n = 153)	P-value*
White matter hyperintensity volume (median [IQR]) <i>Missing, n</i>	2.56 [0.67 – 6.25] 73	1.66 [0.43 – 5.51] 32	3.90 [1.40 – 7.20] 41	0.0011
Anterior (IM1M2) LVO, n (%)	241 (68.3%)	131 (65.5%)	110 (71.9%)	0.2069
TOAST Subtype, n (%)				
Cardioembolism	98 (27.8%)	44 (22.0%)	54 (35.3%)	0.0291
Large-artery atherosclerosis	183 (51.8%)	114 (57.0%)	69 (45.1%)	
Small vessel occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Stroke of undetermined etiology	61 (17.3%)	34 (17.0%)	27 (17.7%)	
Stroke of other determined etiology	11 (3.1%)	8 (4.0%)	3 (2.0%)	
NIHSS at admission (median [IQR]) <i>Missing, n</i>	5 [2 – 13] 12	3 [1 – 8] 6	8 [3 – 18] 6	< 0.0001
NIHSS at admission, n (%)				
No stroke symptoms (0)	47 (13.8%)	40 (20.6%)	7 (4.8%)	< 0.0001
Minor stroke (1-4)	118 (34.6%)	79 (40.7%)	39 (26.5%)	
Moderate stroke (5-15)	101 (29.6%)	52 (26.8%)	49 (33.3%)	
Moderate/severe stroke (16-20)	43 (12.6%)	16 (8.2%)	27 (18.4%)	
Severe stroke (21-42)	32 (9.4%)	7 (3.6%)	25 (17.0%)	
<i>Missing</i>	12	6	6	
Treatment, n (%)				
IV tPA	30 (8.5%)	18 (9.0%)	12 (7.8%)	0.4829
Mechanical thrombectomy	15 (4.3%)	9 (4.5%)	6 (3.9%)	
IV tPA and mechanical thrombectomy	24 (6.8%)	10 (5.0%)	14 (9.2%)	
None	284 (80.5%)	163 (81.5%)	121 (79.1%)	
IV tPA Treatment, n (%)	54 (15.3%)	28 (14.0%)	26 (17.0%)	0.4586
TICI reperfusion score among thrombectomy treatments, n (%)				
mTICI 0	6 (15.4%)	0 (0.00%)	6 (30.0%)	0.0074
mTICI 1	0 (0.00%)	0 (0.00%)	0 (0.00%)	
mTICI 2A	2 (5.1%)	0 (0.0%)	2 (10.0%)	
mTICI 2B	14 (35.9%)	7 (36.8%)	7 (35.0%)	
mTICI 3	17 (43.6%)	12 (63.2%)	5 (25.0%)	
Secondary intracerebral hemorrhage, n (%)	54 (15.3%)	28 (14.0%)	26 (17.0%)	0.4586

*P-value: Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were compared using Fisher's exact tests.

Table 11. Imputed data multivariable model for favorable functional outcome for encounters with large vessel occlusion (all $p < 0.05$)

Odds Ratio Estimates for LVO Encounters				
(n = 353)				
Effect	OR	95% CI		P-Value
WMH Volume (1 unit increase for volume ≤ 4)	0.741	0.595	0.923	0.0065
WMH Volume (1 unit increase for volume > 4)	1.066	0.993	1.144	
Age	0.972	0.952	0.994	0.0114
Dyslipidemia	0.495	0.274	0.895	0.0199
Smoking Ever vs Never	2.504	1.418	4.424	0.0016
Anemia	0.231	0.093	0.573	0.0016
COPD	0.426	0.199	0.912	0.0280
Family History of Stroke	0.508	0.278	0.929	0.0279
NIHSS at Admission: Minor vs No Symptoms	0.333	0.126	0.877	< 0.0001
NIHSS at Admission: Moderate vs No Symptoms	0.166	0.061	0.452	
NIHSS at Admission: Moderate/Severe vs No Symptoms	0.087	0.028	0.271	
NIHSS at Admission: Severe vs No Symptoms	0.047	0.013	0.170	